Amal Mohammad EL-Naggar

Dr. Amal Mohammad EL-Naggar

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
HZHai-Feng Zhang
Hai-Feng Zhang
CHChristopher S. Hughes
Christopher S. Hughes
WLWei Li
Wei Li
JHJian-Zhong He
Jian-Zhong He
SDSurdez Didier
Surdez Didier
Poul H SorensenPoul H Sorensen
Poul H Sorensen
Cancer cells must overcome anoikis (detachment-induced death) to successfully metastasize. Using proteomic screens, we found that distinct oncoproteins upregulate IL1 receptor accessory protein (IL1RAP) to suppress anoikis. IL1RAP is directly induced by oncogenic fusions of Ewing sarcoma, a highly metastatic childhood sarcoma. IL1RAP inactivation triggers anoikis and impedes metastatic dissemination of Ewing sarcoma cells. Mechanistically, IL1RAP binds the cell-surface system Xc− transporter to enhance exogenous cystine uptake, thereby replenishing cysteine and the glutathione antioxidant. Under cystine depletion, IL1RAP induces cystathionine gamma lyase (CTH) to activate the transsulfuration pathway for de novo cysteine synthesis. Therefore, IL1RAP maintains cyst(e)ine and glutathione pools, which are vital for redox homeostasis and anoikis resistance. IL1RAP is minimally expressed in pediatric and adult normal tissues, and human anti-IL1RAP antibodies induce potent antibody-dependent cellular cytotoxicity of Ewing sarcoma cells. Therefore, we define IL1RAP as a new cell-surface target in Ewing sarcoma, which is potentially exploitable for immunotherapy. Significance: Here, we identify cell-surface protein IL1RAP as a key driver of metastasis in Ewing sarcoma, a highly aggressive childhood sarcoma. Minimal expression in pediatric and adult normal tissues nominates IL1RAP as a promising target for immunotherapy. See related commentary by Yoon and DeNicola, p. 2679 . This article is highlighted in the In This Issue feature, p. 2659

31 October 2019 in EMBO Reports
Verified
Journal Article
Open access
PDF file
AEAmal Mohammad EL-Naggar
Amal Mohammad EL-Naggar
SSSyam Prakash Somasekharan
Syam Prakash Somasekharan
YWYemin Wang
Yemin Wang
HCHongwei Cheng
Hongwei Cheng
GNGian Luca Negri
Gian Luca Negri
Poul H SorensenPoul H Sorensen
Poul H Sorensen
Outcomes for metastatic Ewing sarcoma and osteosarcoma are dismal and have not changed for decades. Oxidative stress attenuates melanoma metastasis, and melanoma cells must reduce oxidative stress to metastasize. We explored this in sarcomas by screening for oxidative stress sensitizers, which identified the class I HDAC inhibitor MS‐275 as enhancing vulnerability to reactive oxygen species (ROS) in sarcoma cells. Mechanistically, MS‐275 inhibits YB‐1 deacetylation, decreasing its binding to 5′‐UTRs of NFE2L2 encoding the antioxidant factor NRF2, thereby reducing NFE2L2 translation and synthesis of NRF2 to increase cellular ROS. By global acetylomics, MS‐275 promotes rapid acetylation of the YB‐1 RNA‐binding protein at lysine‐81, blocking binding and translational activation of NFE2L2 , as well as known YB‐1 mRNA targets, HIF1A, and the stress granule nucleator, G3BP1 . MS‐275 dramatically reduces sarcoma metastasis in vivo , but an MS‐275‐resistant YB‐1K81‐to‐alanine mutant restores metastatic capacity and NRF2, HIF1α, and G3BP1 synthesis in MS‐275‐treated mice. These studies describe a novel function for MS‐275 through enhanced YB‐1 acetylation, thus inhibiting YB‐1 translational control of key cytoprotective factors and its pro‐metastatic activity.

20 February 2018 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
AEAmal Mohammad EL-Naggar
Amal Mohammad EL-Naggar
Poul H SorensenPoul H Sorensen
Poul H Sorensen

28 August 2019 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
GNGian Luca Negri
Gian Luca Negri
BGBruno M. Grande
Bruno M. Grande
ADAlberto Delaidelli
Alberto Delaidelli
AEAmal Mohammad EL-Naggar
Amal Mohammad EL-Naggar
DCDawn R Cochrane
Dawn R Cochrane
Poul H SorensenPoul H Sorensen
Poul H Sorensen

3 May 2019 in Communications Biology
Verified
Journal Article
Open access
PDF file
AMAlborz Mazloomian
Alborz Mazloomian
SAShinsuke Araki
Shinsuke Araki
MOMomoko Ohori
Momoko Ohori
AEAmal Mohammad EL-Naggar
Amal Mohammad EL-Naggar
DYDamian Yap
Damian Yap
SASamuel Aparicio
Samuel Aparicio
The RNA helicase EIF4A3 regulates the exon junction complex and nonsense-mediated mRNA decay functions in RNA transcript processing. However, a transcriptome-wide network definition of these functions has been lacking, in part due to the lack of suitable pharmacological inhibitors. Here we employ short-duration graded EIF4A3 inhibition using small molecule allosteric inhibitors to define the transcriptome-wide dependencies of EIF4A3. We thus define conserved cellular functions, such as cell cycle control, that are EIF4A3 dependent. We show that EIF4A3-dependent splicing reactions have a distinct genome-wide pattern of associated RNA-binding protein motifs. We also uncover an unanticipated role of EIF4A3 in the biology of RNA stress granules, which sequester and silence the translation of most mRNAs under stress conditions and are implicated in cell survival and tumour progression. We show that stress granule induction and maintenance is suppressed on the inhibition of EIF4A3, in part through EIF4A3-associated regulation of G3BP1 and TIA1 scaffold protein expression.

15 July 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
MKMelanie Kogler
Melanie Kogler
LTLuigi Tortola
Luigi Tortola
GNGian Luca Negri
Gian Luca Negri
ALAlexandra Leopoldi
Alexandra Leopoldi
AEAmal Mohammad EL-Naggar
Amal Mohammad EL-Naggar
JPJosef M Penninger
Josef M Penninger
HACE1 is an E3 ubiquitin ligase with important roles in tumor biology and tissue homeostasis. Loss or mutation of HACE1 has been associated with the occurrence of a variety of neoplasms, but the underlying mechanisms have not been defined yet. Here, we report that HACE1 is frequently mutated in human lung cancer. In mice, loss of Hace1 led to enhanced progression of KRasG12D-driven lung tumors. Additional ablation of the oncogenic GTPase Rac1 partially reduced progression of Hace1−/− lung tumors. RAC2, a novel ubiquitylation target of HACE1, could compensate for the absence of its homolog RAC1 in Hace1-deficient, but not in HACE1-sufficient tumors. Accordingly, ablation of both Rac1 and Rac2 fully averted the increased progression of KRasG12D-driven lung tumors in Hace1−/− mice. In patients with lung cancer, increased expression of HACE1 correlated with reduced levels of RAC1 and RAC2 and prolonged survival, whereas elevated expression of RAC1 and RAC2 was associated with poor prognosis. This work defines HACE1 as a crucial regulator of the oncogenic activity of RAC-family GTPases in lung cancer development.Significance: These findings reveal that mutation of the tumor suppressor HACE1 disrupts its role as a regulator of the oncogenic activity of RAC-family GTPases in human and murine lung cancer.